ScotBio is expanding its R&D programme to explore the potential of cyanobacteria to treat emerging viral pathogens, including coronaviruses. With funding from Medical Research Scotland, a new collaborative partnership with Infection Medicine at the University of Edinburgh will investigate how cyanobacterial extracts, recognized previously for their antiviral activity, can be commercially mass produced using ScotBio’s established production processes and used in the treatment of major emerging viral diseases.